Prolerity Clinical Research, a clinical research site network, has appointed Stacey Johnson as its new Chief Operating Officer (COO). In this role, Johnson will oversee network-wide operations, support strategic initiatives, and drive growth through network expansion.

Johnson is a seasoned clinical research executive with more than 20 years of experience in the clinical research ecosystem, having most recently served as VP of Clinical Operations at WCG, COO at Meridien Clinical Research. With a strong background in all aspects of site operations and quality, she is well-positioned to enhance operational efficiency and expand Prolerity’s market presence.

“We could not be more fortunate to have Stacey join the Prolerity team,” said Jeff Williams, CEO of Prolerity, “Stacey’s leadership, vision, and commitment to the highest standards of quality align perfectly with our mission, and we are confident that she will be instrumental in shaping our future.”

Johnson said, “I am excited to join a team committed to being a high-value site network partner for biopharmaceutical companies and CROs who need sites capable of delivering access to diverse patients to advance their most promising treatments.”